Use of JAK Inhibitors and Systemic Treatments for Atopic Dermatitis

Key Takeaways

• Targeted agents, including JAK inhibitors, are increasingly used in atopic dermatitis management, reflecting their growing acceptance in clinical practice.
• JAK inhibitors are considered for patients with moderate to severe atopic dermatitis, especially when rapid symptom control is required.
• Clinicians assess JAKi versus biologics based on efficacy, safety, and patient-specific factors, tailoring treatment to individual needs.
• Ideal candidates for JAK inhibitors are those unresponsive to topical treatments or biologics, or when other systemic therapies are unsuitable.